Cost-Effectiveness of Sacubitril–Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sacubitril-valsartan therapy reduces cardiovascular mortality compared with enalapril therapy in patients with heart failure with reduced ejection fraction. OBJECTIVE: To evaluate the cost-effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chronic heart failure. DESIGN: Markov decision model. DATA SOURCES: Clinical trials, observational analyses, reimbursement data from the Centers for Medicare & Medicaid Services, drug pricing databases, and Centers for Disease Control and Prevention life tables. TARGET POPULATION: Patients at an average age of 64 years, New York Heart Association (NYHA) class II to IV heart failure, and left ventricular ejection fraction of 0.40 or less. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Treatment with sacubitril-valsartan or lisinopril. OUTCOME MEASURES: Life-years, quality-adjusted life-years (QALYs), costs, heart failure hospitalizations, and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The sacubitril-valsartan group experienced 0.08 fewer heart failure hospitalization, 0.69 additional life-year, 0.62 additional QALY, and $29 203 in incremental costs, equating to a cost per QALY gained of $47 053. The cost per QALY gained was $44 531 in patients with NYHA class II heart failure and $58 194 in those with class III or IV heart failure. RESULTS OF SENSITIVITY ANALYSIS: Sacubitril-valsartan treatment was most sensitive to the duration of improved outcomes, with a cost per QALY gained of $120 623 if the duration was limited to the length of the trial (median, 27 months). No variations in other parameters caused the cost to exceed $100 000 per QALY gained. LIMITATION: The benefit of sacubitril-valsartan is based on a single clinical trial. CONCLUSION: Treatment with sacubitril-valsartan provides reasonable value in reducing cardiovascular mortality and morbidity in patients with NYHA class II to IV heart failure. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs and Institute for Clinical and Economic Review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · cited 11×
“We used losartan as the alternative ARB therapy because it has effects similar to those of valsartan but lower cost (6, 8).”
BackgroundInfluentialRecommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455 · cited 2×
“We used a societal perspective, with inclusion of all health care costs regardless of payer, and adhered to best practices (12, 13).”
BackgroundMethodUpdating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1405158 · Cited by 2,249 · cited 1×
“gross domestic product per capita) considered not cost-effective (10, 11).”
BackgroundPacker, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Rydén, L., Thygesen, K., & Uretsky, B. F. (1999) · Circulation · doi:10.1161/01.cir.100.23.2312 · Cited by 1,244 · cited 1×
“Furthermore, there is limited evidence of dose-responsiveness between moderate and high doses of ACEIs or a comparative benefit of ARBs, suggesting that the comparator group was appropriate (14, 37, 38).”
BackgroundPacker, M., McMurray, J. J. V., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013748 · Cited by 673
Caro, J. J., Briggs, A. H., Siebert, U., & Kuntz, K. M. (2012) · Medical Decision Making · doi:10.1177/0272989x12454577 · Cited by 520
Rogers, J. K., McMurray, J. J. V., Pocock, S. J., Zannad, F., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., & Pitt, B. (2012) · Circulation · doi:10.1161/circulationaha.112.110536 · Cited by 224
Research works printed but not linked: 37
- 10.1161/HHF.0b013e318291329a · DOI · Paper page
- 10.1016/j.ccl.2013.09.002 · DOI · Paper page
- 10.1177/1060028015593093 · DOI
- 10.1016/j.jacc.2013.05.019 · DOI · Paper page
- 10.1016/j.amjcard.2004.08.097 · DOI
- 10.1016/j.jacc.2014.03.016 · DOI · Paper page
- 10.1002/14651858.CD003040.pub2 · DOI · Paper page
- 10.1093/eurheartj/ehv186 · DOI · Paper page
- 10.1001/archinte.158.10.1081 · DOI · Paper page
- 10.1016/j.ahj.2014.11.007 · DOI
- 10.1016/j.ehj.2004.07.007 · DOI
- Arias E, 2013, Natl Vital Stat Rep, 61, 1
- 10.1161/CIRCOUTCOMES.110.957225 · DOI · Paper page
- 10.1111/j.1524-4733.2008.00425.x · DOI
- 10.1056/NEJMc1509753 · DOI · Paper page
- 10.7326/M15-2587 · doi:10.7326/m15-2587
- 10.1161/CIRCHEARTFAILURE.116.002837 · DOI
- 10.1016/j.jchf.2016.02.012 · DOI
- 10.11909/j.issn.1671-5411.2015.05.010 · DOI
- 10.1002/phar.1629 · DOI
- 10.1016/j.jacc.2015.01.033 · DOI
- 10.1093/eurheartj/ehu501 · doi:10.1093/eurheartj/ehu501
- 10.1056/NEJM199108013250501 · DOI · Paper page
- 10.1016/0002-9149(92)90683-P · DOI
- 10.1016/S0735-1097(00)01025-1 · DOI
- 10.1001/jamacardio.2016.1747 · DOI · Paper page
- 10.1016/j.jchf.2016.02.007 · DOI
- 10.1001/jamainternmed.2015.7661 · DOI
- 10.1016/S0735-1097(16)31350-X · doi:10.1016/s0735-1097(16)31350-x
- 10.1016/S0140-6736(03)13800-7 · DOI · Paper page
- 10.1053/euhj.1998.1098 · DOI · Paper page
- 10.1001/jama.2015.17632 · DOI
- 10.1016/j.amjcard.2006.08.065 · DOI
- 10.2165/11314830-000000000-00000 · DOI · Paper page
- 10.1093/eurheartj/ehv330 · DOI · Paper page
- 10.1016/j.ahj.2006.11.010 · DOI
- 10.1016/j.amjcard.2012.05.059 · DOI
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationMartin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
Kazi, D. S., Bellows, B. K., Baron, S. J., Shen, C., Cohen, D. J., Spertus, J. A., Yeh, R. W., Arnold, S. V., Sperry, B. W., Maurer, M. S., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.045093 · Cited by 263
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Grant, A. D. M., Chew, D. S., Howlett, J. G., & Miller, R. J. H. (2020) · CJC Open · doi:10.1016/j.cjco.2020.05.009 · Cited by 12
Metadata
- Authors
- Sandhu, A. T., Ollendorf, D. A., Chapman, R. H., Pearson, S. D., & Heidenreich, P. A.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-11-15
- Volume
- 165
- Issue
- 10
- Pages
- 681-689
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2517239280
- Cited by
- 80
- References
- 7
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.